IP Library › Granted Patent US 10,137,101
Granted Patent B2
US 10,137,101 · App. 15/337,707 · Granted Nov 27, 2018

Alkylamido compounds and uses thereof

Inventors: Sergio Baroni (Villa D'adda, IT); Salvatore Bellinvia (Mendrisio, CH); Francesca Viti (Salorino, CH)
Assignee: Nogra Pharma Limited
A61K31/196A61K8/42A61Q5/00A61Q7/00A61Q19/02A61Q19/06A61Q19/08C07C233/54C07C235/38C07D307/79C07D319/08A61K2800/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,137,101
App. No.
15/337,707
Granted
Nov 27, 2018
Kind
B2
Abstract

Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.

Claims (8)

1. A method of treating acne in a subject in need thereof, the method comprising administering a therapeutically effective amount of N-acetyl-(S)-3-(4-aminophenyl)-2-methoxypropionic acid, or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof.

2. The method of claim 1 , wherein the acne is at least one of: acne vulgaris, comedo-type acne, polymorphic acne, acne rosacea, nodulocystic acne, acne conglobata, senile acne, secondary acne, solar acne, acne medicamentosa or occupational acne, or acne hyperseborrhoea.

3. The method of claim 1 , wherein N-acetyl-(S)-3-(4-aminophenyl)-2-methoxypropionic acid, or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof, is administered orally or topically.

4. A method of treating acne in a subject in need thereof, the method comprising administering a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises:

a therapeutically effective amount of N-acetyl-(S)-3-(4-aminophenyl)-2-methoxypropionic acid, or a pharmaceutically acceptable salt or a pharmaceutically acceptable N-oxide thereof; and

a pharmaceutically acceptable carrier.

5. The method of claim 4 , wherein the acne is at least one of: acne vulgaris, comedo-type acne, polymorphic acne, acne rosacea, nodulocystic acne, acne conglobata, senile acne, secondary acne, solar acne, acne medicamentosa or occupational acne, and acne hyperseborrhoea.

6. The method of claim 4 , wherein the pharmaceutical composition is administered orally or topically.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2018
From: BARONI, SERGIO; BELLINVIA, SALVATORE; VITI, FRANCESCA
To: GIULIANI INTERNATIONAL, LTD.
Reel/Frame 045119/0706 →
CHANGE OF NAME Recorded Mar 6, 2018
From: GIULIANI INTERNATIONAL LIMITED
To: NOGRA PHARMA LIMITED
Reel/Frame 045119/0716 →
Priority Claims (1)
EP 09425056 · Feb 16, 2009 · regional
Continuity (5)
Continuation 14255255 · Apr 17, 2014
Continuation 13201786
Provisional Application 61287461 · Dec 17, 2009
Provisional Application 61179062 · May 18, 2009
Related Publication 20170172956A1 · Jun 22, 2017
Cited By (2)
US 12,291,494 US 12,509,416